MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$14,218K
Free Cash flow
-$41,938K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales of marketable securities
Proceeds from medtronic term loa...
Proceeds from the royalty purcha...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Personnel and consulting costs
Development costs-Clinical Devel...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Total revenue-Partnership Revenue
-
30,751
2,120
-
Total revenue-Product
198
166
445
-
Cost of product revenues
57
51
139
-
Development costs-Non Clinical Development Costs
7,429
5,099
12,880
-
Development costs-Clinical Development Costs
8,534
3,643
9,302
-
Personnel and consulting costs
17,611
9,545
20,483
-
Stock-based compensation
5,356
2,750
9,228
-
Depreciation expense
-
-
245
-
Depreciation and amortization expense
186
327
-
-
Other segment expenses
2,882
2,739
8,849
-
Interest expense (income), net
-2,589
-763
-385
-
Net loss
-44,446
6,245
-20,828
-38,118
Depreciation and amortization
186
82
81
164
Stock-based compensation
5,356
2,750
3,013
6,215
Non-cash interest expense on liability related to the royalty purchase agreement
3,111
1,287
761
-
Accrued interest expense on liability related to the note payable
442
-
-
-
Gain on sale of strategic investments
2,286
-
-
-
Accretion and interest related to marketable securities
476
320
330
161
Non-cash lease expense
325
157
153
297
Change in the fair value of derivative liability
289
254
-
-
Deferred revenue
-
-13,308
-721
-1,399
Amortization of deferred financing fees
129
64
59
92
Accounts receivable
-44
43
-31
-9
Inventory
-60
-55
181
11
Prepaid expenses and other assets
-14
-593
-139
-148
Accounts payable, accrued expenses and other liabilities
-3,311
566
3,412
888
Operating lease liabilities - current and non-current
-359
-144
-139
-267
Net cash used in operating activities
-41,500
-2,270
-14,550
-32,143
Purchases of property and equipment
438
33
310
146
Sales of marketable securities
38,791
7,950
9,507
32,403
Purchases of marketable securities
56,125
25,629
47,781
2,902
Sale of strategic investments
4,781
-
-
-
Net cash (used in) provided by investing activities
-12,991
-17,712
-38,584
29,355
Proceeds from sale of common stock and pre-funded warrants, net of issuance costs
-
0
57,780
-
Proceeds from the royalty purchase agreement
15,000
0
20,000
-
Proceeds from issuance of series a preferred stock
-
12,557
-
-
Repayment of royalty liability
-
972
-
-
Proceeds from medtronic term loan
20,000
-
-
-
Proceeds from at-the-market offering, net of issuance costs
5,855
1,543
-
-
Proceeds from exercise of stock options
34
0
0
91
Restricted stock units withheld for tax
616
468
269
815
Deferred financing costs
-
0
1,114
-
Net cash provided by (used in) financing activities
40,273
12,660
76,397
-724
Net decrease in cash and cash equivalents
-14,218
-7,322
23,263
-3,512
Cash and cash equivalents, beginning of the period
34,690
42,012
22,261
-
Cash and cash equivalents, end of the period
20,472
34,690
42,012
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from medtronic
term loan
$20,000K
Proceeds from the royalty
purchase agreement
$15,000K
Proceeds from
at-the-market offering, net of...
$5,855K
Proceeds from exercise of
stock options
$34K
(-62.64%↓ Y/Y)
Net cash provided by
(used in) financing...
$40,273K
(5662.57%↑ Y/Y)
Canceled cashflow
$616K
Net decrease in cash
and cash...
-$14,218K
(-304.84%↓ Y/Y)
Canceled cashflow
$40,273K
Stock-based compensation
$5,356K
(-13.82%↓ Y/Y)
Non-cash interest
expense on liability...
$3,111K
Accrued interest
expense on liability...
$442K
Non-cash lease expense
$325K
(9.43%↑ Y/Y)
Depreciation and
amortization
$186K
(13.41%↑ Y/Y)
Amortization of deferred
financing fees
$129K
(40.22%↑ Y/Y)
Inventory
-$60K
(-645.45%↓ Y/Y)
Accounts receivable
-$44K
(-388.89%↓ Y/Y)
Prepaid expenses and
other assets
-$14K
(90.54%↑ Y/Y)
Sales of marketable
securities
$38,791K
(19.71%↑ Y/Y)
Sale of strategic
investments
$4,781K
Restricted stock units
withheld for tax
$616K
(-24.42%↓ Y/Y)
Net cash used in
operating activities
-$41,500K
(-29.11%↓ Y/Y)
Canceled cashflow
$9,667K
Net cash (used in)
provided by investing...
-$12,991K
(-144.25%↓ Y/Y)
Total
revenue-Product
$198K
Canceled cashflow
$43,572K
Net loss
-$44,446K
(-16.60%↓ Y/Y)
Canceled cashflow
$198K
Accounts payable,
accrued expenses and...
-$3,311K
(-472.86%↓ Y/Y)
Gain on sale of
strategic investments
$2,286K
Accretion and interest
related to marketable...
$476K
(195.65%↑ Y/Y)
Operating lease
liabilities - current and...
-$359K
(-34.46%↓ Y/Y)
Change in the fair value
of derivative...
$289K
Purchases of marketable
securities
$56,125K
(1834.01%↑ Y/Y)
Purchases of property and
equipment
$438K
(200.00%↑ Y/Y)
Personnel and consulting
costs
$17,611K
Development costs-Clinical
Development Costs
$8,534K
Development costs-Non
Clinical Development...
$7,429K
Stock-based compensation
$5,356K
(-13.82%↓ Y/Y)
Other segment
expenses
$2,882K
Interest expense
(income), net
-$2,589K
Depreciation and
amortization expense
$186K
Cost of product
revenues
$57K
Buy us a coffee
Orchestra BioMed Holdings, Inc. (OBIO)
Orchestra BioMed Holdings, Inc. (OBIO)